Lancet: dual mobility cuts reops threefold

A randomized trial in *The Lancet* adds hard-outcome evidence to a long-running orthopedic question: does a dual-mobility cup actually prevent the complications that make hip-fracture arthroplasty go wrong? In the DUALITY trial, patients who received a dual-mobility total hip replacement after a displaced femoral neck fracture were markedly less likely to need a repeat operation than patients given a standard total hip replacement. The study also found a large reduction in postoperative dislocation, the complication dual-mobility designs were built to address. For surgeons and hospitals, the result matters because this is not a registry signal or a device theory paper — it is a large randomized comparison in routine fracture care. ### What exactly was tested in this trial? The DUALITY trial compared two versions of total hip replacement in older adults with displaced femoral neck fractures: a standard total hip replacement and a dual-mobility total hip replacement. The dual-mobility design places a small femoral head inside a larger polyethylene liner, creating a second articulation intended to improve stability. (thelancet.com) The Lancet paper describes DUALITY as an international, multicenter, randomized, controlled superiority trial. Queen Mary University of London and Uppsala University said the study included about 1,600 patients treated at 44 hospitals — 20 in Sweden and 24 in the UK — and enrolled patients aged 65 or older who were considered suitable for total hip replacement after fracture. (thelancet.com) ### Why is dislocation the complication everyone focuses on? Dislocation is the most common early surgical complication after total hip replacement for hip fracture, according to the Lancet article. When it happens, patients can need emergency admission, sedation or anesthesia for reduction, and sometimes another operation. Nils Hailer of Uppsala University, a consultant orthopedic surgeon and study researcher, said in the university release that a dislocated hip replacement is “extremely painful” and can leave patients unable to trust the implant afterward, while also straining healthcare resources. (thelancet.com) That is why a reduction in dislocation is clinically important even before looking at broader complication rates. ### What were the key numbers? One-year dislocation rates were 1.3% in the dual-mobility group and 4.2% in the standard total hip replacement group, according to Queen Mary and Uppsala. Those institutions said that translated to a 70% lower risk of dislocation with the dual-mobility implant. (uu.se) The preliminary card summary’s “threefold” framing reflects the repeat-surgery finding: patients receiving the dual-mobility implant were about three times less likely to undergo reoperation than those receiving a standard implant, based on the trial report and linked coverage. That makes the study notable because it ties implant choice to a concrete downstream event, not just a radiographic or technical endpoint. (qmul.ac.uk) ### Did the stability gain come with tradeoffs? Queen Mary and Uppsala said the trial found no increase in infection or death in the dual-mobility group. Uppsala also said there was no difference in quality of life during the first postoperative year, even as overall surgical complication risk was lower with the dual-mobility cup. (thelancet.com) That matters because dual-mobility implants have often been discussed as a stability solution with lingering questions about broader safety or complexity. In this trial, the institutions said surgeons were already familiar with both implant types and that no new technology or training was required to use the dual-mobility option. (qmul.ac.uk) ### Which patients does this apply to — and which does it not? The study applies to older adults with displaced femoral neck fractures who were judged suitable for total hip replacement, not to every patient with a hip fracture. Queen Mary said the fracture type studied represents roughly half of hip fractures globally, which is one reason the findings could be relevant to a large surgical population. (qmul.ac.uk) The next step for readers who want the details is the full DUALITY paper and its linked Lancet commentary, both published in July 2026, along with the institutional releases from Queen Mary University of London and Uppsala University naming the investigators and participating centers. (thelancet.com) (qmul.ac.uk)